RegenXBio (RGNX) Stock Statistics & Valuation Metrics

RegenXBio has a market cap or net worth of $453.68M. The enterprise value is $679.73M.

RegenXBio has 51,612,984 shares outstanding. The number of shares has decreased by -2.65% in one year.

RegenXBio’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -42.11%.

The current PE Ratio of RegenXBio is ―. RegenXBio’s PEG ratio is 0.21.

In the last 12 months, RegenXBio had revenue of 170.44M and earned -193.88M in profits. Earnings per share was -3.76.

In the last 12 months, operating cash flow was -123.96M and capital expenditures -2.41M, giving a free cash flow of -126.38M billion.

RegenXBio pays an annual dividend of ―, resulting in a dividend yield of ―

RegenXBio upcoming earnings date is May 6, 2026, Before Open (Confirmed).

RegenXBio as a current ratio of 2.38, with Debt / Equity ratio of 253.59%

In the past 12 months, RegenXBio has paid 0.00 in taxes.

RegenXBio EV to EBITDA ratio is -6.65, with an EV/FCF ratio of -7.67.

RegenXBio has $230.07M in cash and marketable securities with $260.52M in debt, giving a net cash position of -$30.45M billion.

Gross margin is 52.88%, with operating margin of -94.58%, and net profit margin of -113.75%.

The average price target for RegenXBio is $30.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy